Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064064 · ClinicalTrials.gov registry record · Phase 2
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064064 is a Phase 2 study that has completed, run by Vion Pharmaceuticals.
The verdict
NCT00064064, a Phase 2 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with 3-AP in treating patients who have metastatic non-small cell lung cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG triapine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064064
The ClinicalTrials.gov registry entry for NCT00064064 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00064064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064064 about?
NCT00064064 is a clinical study titled "3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them m...
What is the current status of trial NCT00064064?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00064064?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00064064?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.